A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer

Date Added
August 2nd, 2022
PRO Number
Pro00121443
Researcher
Mariam Alexander

List of Studies

Keywords
Cancer, Cancer/Lung, Lung
Summary

This study is for patients who have been diagnosed with advanced non-small cell lung cancer. The purpose of this study is to compare the usual treatment alone to using SBRT plus the usual treatment. This study will help the study doctors find out if this different approach is better than the usual approach. To decide if it is better, the study doctors will be looking to see if the addition of SBRT increases the life of patients by 6 months or more compared to the usual approach. The study drugs are nivolumab and ipilimumab. Participants can expect to be on this study for up to 2 years.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

PHASE III TRIAL OF SALVAGE STEREOTACTIC RADIOSURGERY (SRS) OR SRS + HIPPOCAMPALAVOIDANT WHOLE BRAIN RADIOTHERAPY (HA-WBRT) FOR FIRST OR SECOND DISTANT BRAIN RELAPSE AFTER UPFRONT SRS WITH BRAIN METASTASIS VELOCITY ≥4 BRAIN METASTASES/YEAR

Date Added
August 4th, 2022
PRO Number
Pro00122545
Researcher
Charlotte Rivers

List of Studies


Keywords
Cancer/Brain
Summary

This study is for men or women who received stereotactic radiosurgery to treat cancer that spread to their brain, and now the cancer has returned in other areas of the brain. This study is being done to see if by adding radiation therapy called whole-brain radiation therapy that avoids the hippocampus to preserver memory plus medication approved to treat dementia can extend these patients lives.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Phase III Study of Local or Systemic Therapy INtensification DIrected by PET in Prostate CAncer Patients with Post-ProstaTEctomy Biochemical Recurrence (INDICATE)

Date Added
August 5th, 2022
PRO Number
Pro00122143
Researcher
Harriet Eldredge-Hindy

List of Studies

Keywords
Cancer/Genitourinary, Prostate
Summary

This study is for men with prostate cancer that has come back after surgery. This study is being done to see if PET/CT scans help provide more tailored treatment recommendations and outcomes for men who have prostate cancer after radical prostatectomy (RP) and will adding focal, metastasis directed radiation treatment (e.g.., stereotactic radiation) and/or additional systemic therapy (e.g., apalutamide) to standard of care treatment help to delay progression of prostate cancer in men who have already had an RP and now have recurrence?

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
(843) 792-9321
hcc-clinical-trials@musc.edu

MEPITEL FILM FOR THE REDUCTION OF RADIATION DERMATITIS IN BREAST CANCER PATIENTS UNDERGOING POST-MASTECTOMY RADIATION THERAPY: A RANDOMIZED PHASE III CLINICAL TRIAL

Date Added
August 15th, 2022
PRO Number
Pro00122724
Researcher
Jennifer Harper

List of Studies


Keywords
Cancer/Breast
Summary

This study is for patients who have been diagnosed with breast cancer and their doctor has recommended that they receive radiation therapy after their mastectomy to reduce the risk of their breast cancer coming back. This study is being done to see if the severity of skin redness and peeling in the area of radiation can be reduced by applying Mepitel Film during radiation therapy.

Institution
MUSC
Recruitment Contact
Barbara Roe
843-652-1607
broe@tidelandshealth.org

ACCESS: A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies.

Date Added
August 16th, 2022
PRO Number
Pro00118834
Researcher
Michelle Hudspeth

List of Studies


Keywords
Adolescents, Cancer, Pediatrics, Transplant
Summary

This study is for patients that have had hematopoietic stem cell transplants and/or have been donors. The purpose of this study is to see how well transplant works in adults with a MMUD using stem cells from a donor's blood, and in children with a MMUD using stem cells from a donor's bone marrow.This study treatment does not include any investigational drugs. The medicines and procedures in this study are standard for transplant. Participants can expect to be on this study for approximately 1 year.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

PHASE III TRIAL OF IMMUNOTHERAPY-BASED COMBINATION THERAPY WITH OR WITHOUT CYTOREDUCTIVE NEPHRECTOMY FOR METASTATIC RENAL CELL CARCINOMA (PROBE TRIAL)

Date Added
September 1st, 2022
PRO Number
Pro00122590
Researcher
Robert Grubb

List of Studies


Keywords
Cancer/Genitourinary, Kidney
Summary

This study is for patients with kidney cancer that has spread outside of their kidney. The study is looking to see if adding surgery to the usual combination of drugs can lower the chances of kidney cancer growing or spreading.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Identification of Differences in Verb Learning between Late Talkers and Typically Developing Children

Date Added
October 4th, 2022
PRO Number
Pro00123522
Researcher
Sabrina Horvath

List of Studies

Keywords
Language, Pediatrics, Speech Disorders
Summary

This study explores the best way to teach two-year-old toddlers new verbs, and whether there are differences in what is best between late talkers and typically developing children. In a series of two, one-hour visits, children will watch videos on an eye-tracker, which will capture their face and gaze patterns. This data will be analyzed to see how children are making sense of what they are hearing. In one task, we ask whether it is better for children to hear a new verb before they see the action it denotes, or whether it is better to see the new action before hearing the verb. In the second task, we consider how quickly children are able to make sense of the language they hear, and whether this has any relationship to how they learn new verbs (Task 1). Results will help shape new clinical interventions for late talkers.

Institution
MUSC
Recruitment Contact
Sabrina Horvath
843-792-9363
horvaths@musc.edu

A PHASE II/III STUDY OF PACLITAXEL/CARBOPLATIN ALONE OR COMBINED WITH EITHER TRASTUZUMAB AND HYALURONIDASE-OYSK (HERCEPTIN HYLECTA) OR PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF (PHESGO) IN HER2 POSITIVE, STAGE I-IV ENDOMETRIAL SEROUS CARCINOMA OR CARCINOSARCOMA

Date Added
January 3rd, 2023
PRO Number
Pro00124595
Researcher
Whitney Graybill

List of Studies


Keywords
Cancer/Gynecological
Summary

This study is for women with endometrial cancer. This study is being done to see if by adding a drug or drugs that target HER2 proteins in addition to the usual combination of chemotherapy drugs.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
(843) 792-9321
hcc-clinical-trials@musc.edu

The efficacy of the Smart Pass filter to Reduce the Risk for inappropriate subcutaneous implantable cardioverter-defibrillator shocks from myopotential interference

Date Added
January 23rd, 2023
PRO Number
Pro00117025
Researcher
Michael Gold

List of Studies


Keywords
Heart
Summary

This study is enrolling participants who are already implanted with a S-ICD device (Subcutaneous Implantable Cardioverter Defibrillator, which is a device designed to monitor heart rhythms and deliver a shock to the heart to stop life threatening heart rhythms), and are undergoing a routine outpatient clinic follow up appointment to have their S-ICD checked. The aim of the study is to see if a feature in the device can recognize muscle movement and differentiate movement from irregular heart signals. The study involves doing some simple arm exercises while collecting device data, both with this feature turn on and then with it turned off. Participants will be randomized to either have the feature turned on or off initially then it will be programmed the alternative way and the same exercise testing will be repeated. The study will involve just one visit.

Institution
MUSC
Recruitment Contact
Natalie Drain
843-876-5037
drain@musc.edu

BLINDED REFERENCE SET FOR MULTICANCER EARLY DETECTION BLOOD TESTS

Date Added
January 24th, 2023
PRO Number
Pro00125723
Researcher
Brian Hess

List of Studies


Keywords
Cancer
Summary

This study is for patients with cancer and is being done to see if blood samples from patients with and without certain types of cancer help researchers develop a future blood test for use in detecting cancer early.

Institution
MUSC
Recruitment Contact
Barbara Roe
843-652-1607
broe@tidelandshealth.org



-- OR --